{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:28:05Z","timestamp":1789097285700,"version":"build-2803163510"},"reference-count":141,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystemic disease, i.e., influencing various organ systems beyond the liver and, thus, contributing to comorbidities. Characterized by excessive fat accumulation in the hepatocytes, MASLD is frequently linked to metabolic syndrome components, such as obesity, insulin resistance, dyslipidemia, and hypertension. Therefore, exploring the intricate connection between MASLD and other organ systems, including the eyes, seems to be essential. In this context, retinopathy has been investigated for its potential association with MASLD, since both conditions share common pathogenetic pathways. Chronic low-grade inflammation, oxidative stress, insulin resistance, and endothelial dysfunction are only some of those mechanisms contributing to disease progression and, possibly, determining the bidirectional interplay between the liver and retinal pathology. This narrative review aims to summarize data concerning the multisystemicity of MASLD, primarily focusing on its potential association with the eyes and, particularly, retinopathy. Identifying this possible association may emphasize the need for early screening and integrated management approaches that address the liver and eyes as interconnected components within the framework of a systemic disease. Further research is necessary to delineate the precise mechanisms and develop targeted interventions to mitigate the bidirectional impact between the liver and eyes, aiming to reduce the overall burden of disease and improve patient outcomes.<\/jats:p>","DOI":"10.3390\/medicina61010038","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T13:26:25Z","timestamp":1735651585000},"page":"38","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-9195","authenticated-orcid":false,"given":"Myrsini","family":"Orfanidou","sequence":"first","affiliation":[{"name":"First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"},{"name":"First Department of Ophthalmology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[{"name":"First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/apt.17158","article-title":"Review article: The epidemiologic burden of non-alcoholic fatty liver disease across the world","volume":"56","author":"Henry","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/liv.15852","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa","volume":"44","author":"Younossi","year":"2024","journal-title":"Liver Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"155936","DOI":"10.1016\/j.metabol.2024.155936","article-title":"Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management","volume":"157","author":"Polyzos","year":"2024","journal-title":"Metabolism"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity (2024). EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes. Facts., 17, 374\u2013444.","DOI":"10.1159\/000539371"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20420188221145549","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: A multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_8","first-page":"691","article-title":"MASLD: A systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","article-title":"Nonalcoholic Fatty Liver Disease. Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease","volume":"46","author":"Polyzos","year":"2012","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_10","first-page":"127","article-title":"The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease","volume":"13","author":"Polyzos","year":"2009","journal-title":"Hippokratia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","article-title":"Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease","volume":"52","author":"Makri","year":"2021","journal-title":"Arch. Med. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Makri, E.S., Makri, E., and Polyzos, S.A. (2022). Combination Therapies for Nonalcoholic Fatty Liver Disease. J. Pers. Med., 12.","DOI":"10.3390\/jpm12071166"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1017\/S0029665121003815","article-title":"Non-alcoholic fatty liver disease: A multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function","volume":"81","author":"Bilson","year":"2022","journal-title":"Proc. Nutr. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109776","DOI":"10.1016\/j.clim.2023.109776","article-title":"Potential impact of trained innate immunity on the pathophysiology of metabolic dysfunction-associated fatty liver disease","volume":"256","author":"Kountouras","year":"2023","journal-title":"Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate Immunity and Inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101111","DOI":"10.1016\/j.molmet.2020.101111","article-title":"Genetic and epigenetic factors determining NAFLD risk","volume":"50","author":"Jonas","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Juanola, O., Martinez-Lopez, S., Frances, R., and Gomez-Hurtado, I. (2021). Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18105227"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.7150\/thno.55795","article-title":"Organ-organ communication: The liver\u2019s perspective","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/apt.16575","article-title":"Review article: Non-alcoholic fatty liver disease and cardiovascular diseases: Associations and treatment considerations","volume":"54","author":"Polyzos","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: A clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Marcuccilli, M., and Chonchol, M. (2016). NAFLD and Chronic Kidney Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040562"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00030","DOI":"10.1097\/IN9.0000000000000030","article-title":"Growth hormone and nonalcoholic fatty liver disease","volume":"5","author":"Ma","year":"2023","journal-title":"Immunometabolism"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1136\/gutjnl-2024-332491","article-title":"Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis","volume":"73","author":"Mantovani","year":"2024","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ra\u0111enovi\u0107, S.S., Pupovac, M., Andji\u0107, M., Bila, J., Sre\u0107kovi\u0107, S., Gudovi\u0107, A., Draga\u0161, B., and Radunovi\u0107, N. (2022). Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). Biomedicines, 10.","DOI":"10.3390\/biomedicines10010131"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sleep.2022.04.006","article-title":"Obstructive sleep apnea, intermittent hypoxia and non-alcoholic fatty liver disease","volume":"95","author":"Ji","year":"2022","journal-title":"Sleep Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"155676","DOI":"10.1016\/j.metabol.2023.155676","article-title":"Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease","volume":"147","author":"Polyzos","year":"2023","journal-title":"Metabolism"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/dom.14774","article-title":"Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications","volume":"24","author":"Vachliotis","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yang, Y.J., and Kim, D.J. (2021). An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052604"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/HC9.0000000000000203","article-title":"The prevalence and risk factors for cognitive impairment in obesity and NAFLD","volume":"7","author":"Wernberg","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Colognesi, M., Gabbia, D., and De Martin, S. (2020). Depression and Cognitive Impairment\u2014Extrahepatic Manifestations of NAFLD and NASH. Biomedicines, 8.","DOI":"10.3390\/biomedicines8070229"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamadermatol.2022.1609","article-title":"Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults","volume":"158","author":"Ruan","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.cgh.2023.02.021","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis","volume":"21","author":"Zamani","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7570\/jomes22021","article-title":"Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease","volume":"31","author":"Huh","year":"2022","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4239\/wjd.v8.i7.317","article-title":"Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia","volume":"8","author":"Mbata","year":"2017","journal-title":"World J. Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jdi.13489","article-title":"Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta-analysis of observational studies","volume":"12","author":"Song","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, G.-H., Yuan, T.-H., Yue, Z.-S., Wang, L., and Dou, G.-R. (2022). The presence of diabetic retinopathy closely associated with the progression of non-alcoholic fatty liver disease: A meta-analysis of observational studies. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1019899"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Orfanidou, M., Ntenti, C., Evripidou, K., Mataftsi, A., Goulas, A., and Polyzos, S.A. (2023). Retinal Vascular Lesions in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. J. Pers. Med., 13.","DOI":"10.3390\/jpm13071148"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1186\/s12967-023-04543-3","article-title":"Insights into the liver-eyes connections, from epidemiological, mechanical studies to clinical translation","volume":"21","author":"Wu","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_49","first-page":"1099","article-title":"Association Between Nonalcoholic Fatty Liver Disease and Intraocular Pressure in Korean Adults","volume":"27","author":"Kwon","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lee, J.-H., Kwon, Y.-J., Lee, H.S., Han, J.H., Joung, B., and Kim, S.J. (2022). Fatty Liver Is an Independent Risk Factor for Elevated Intraocular Pressure. Nutrients, 14.","DOI":"10.3390\/nu14214455"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(17)30544-5","article-title":"Cataracts","volume":"390","author":"Liu","year":"2017","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ceo.13892","article-title":"Cataract and systemic disease: A review","volume":"49","author":"Ang","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"102424","DOI":"10.1016\/j.eclinm.2024.102424","article-title":"Associations of severe liver diseases with cataract using data from UK Biobank: A prospective cohort study","volume":"68","author":"Chen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kang, K.H., Shin, D., Ryu, I.H., Kim, J.K., Lee, I.S., Koh, K., and Yoo, T.K. (2024). Association between cataract and fatty liver diseases from a nationwide cross-sectional study in South Korea. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-50582-7"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e57168","DOI":"10.2196\/57168","article-title":"Association Between Fatty Liver Index and Incidence of Cataract Surgery in Individuals Aged 50 Years and Older Based on the Korean National Health Insurance Service-Health Screening Cohort (NHIS-HEALS) Data: Longitudinal Retrospective Cohort Study","volume":"10","author":"Kim","year":"2024","journal-title":"JMIR Public Health Surveill."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","article-title":"The complement system in age-related macular degeneration","volume":"78","author":"Armento","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1093\/hmg\/ddx228","article-title":"Genetics of age-related macular degeneration (AMD)","volume":"26","author":"DeAngelis","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1073\/pnas.0912019107","article-title":"Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC)","volume":"107","author":"Neale","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Androutsakos, T., Voulgaris, T.A., and Bakasis, A.D. (2022). Liver Fibrosis in Primary Sjogren\u2019s Syndrome. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.889021"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Choi, D.D., Han, K., Oh, S.Y., and Park, K.-A. (2021). Association between metabolic syndrome and incidence of ocular motor nerve palsy. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-02517-3"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Yuan, T.-H., Yue, Z.-S., Zhang, G.-H., Wang, L., and Dou, G.-R. (2021). Beyond the Liver: Liver-Eye Communication in Clinical and Experimental Aspects. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.823277"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101138","DOI":"10.1016\/j.molmet.2020.101138","article-title":"Hepatokines and metabolism: Deciphering communication from the liver","volume":"44","author":"Potthoff","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/TCRM.S352008","article-title":"Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease","volume":"19","author":"Raptis","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2337\/db17-0830","article-title":"Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice","volume":"67","author":"Fu","year":"2018","journal-title":"Diabetes"},{"key":"ref_66","first-page":"335","article-title":"Fibroblast growth factor 21 and its novel association with oxidative stress","volume":"11","year":"2016","journal-title":"Redox Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"109014","DOI":"10.1016\/j.exer.2022.109014","article-title":"Fibroblast growth factor-21 alleviates phenotypic characteristics of dry age-related macular degeneration in mice","volume":"218","author":"Zhao","year":"2022","journal-title":"Exp. Eye Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Ye, W., Wang, Y.-D., and Chen, W.-D. (2022). HGF\/c-Met: A Key Promoter in Liver Regeneration. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.808855"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2174\/157339910793360815","article-title":"Angiogenic growth factors and their inhibitors in diabetic retinopathy","volume":"6","author":"Praidou","year":"2010","journal-title":"Curr. Diabetes Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"104103","DOI":"10.1016\/j.mvr.2020.104103","article-title":"Hepatocyte growth factor prevents pericyte loss in diabetic retinopathy","volume":"133","author":"Yun","year":"2021","journal-title":"Microvasc. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1096\/fba.2019-00074","article-title":"Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization","volume":"2","author":"Lorenc","year":"2020","journal-title":"FASEB BioAdv."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ali, I.I., D\u2019souza, C., Singh, J., and Adeghate, E. (2022). Adropin\u2019s Role in Energy Homeostasis and Metabolic Disorders. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158318"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"H238","DOI":"10.1152\/ajpheart.00449.2020","article-title":"Adropin: A hepatokine modulator of vascular function and cardiac fuel metabolism","volume":"320","author":"Mushala","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1159\/000500106","article-title":"Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease","volume":"28","author":"Kutlu","year":"2019","journal-title":"Med. Princ. Prac."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Santulli, G. (2014). Angiopoietin-like proteins: A comprehensive look. Front. Endocrinol., 5.","DOI":"10.3389\/fendo.2014.00004"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Carbone, C., Piro, G., and Merz, V. (2018). Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020431"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","article-title":"Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8","volume":"321","author":"Davies","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_78","first-page":"e201706","article-title":"ANGPLT3: A novel modulator of lipid metabolism","volume":"2017","author":"Hassan","year":"2017","journal-title":"Glob. Cardiol. Sci. Prac."},{"key":"ref_79","first-page":"34","article-title":"Angiopoietin-like 3 Is a Potential Biomarker for Retinopathy in Type 2 Diabetic Patients","volume":"191","author":"Yu","year":"2018","journal-title":"Arch. Ophthalmol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOH.0000000000000580","article-title":"ANGPTL4: A multifunctional protein involved in metabolism and vascular homeostasis","volume":"27","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"36841","DOI":"10.1074\/jbc.M111.220061","article-title":"Alteration of developmental and pathological retinal angiogenesis in angptl4-deficient Mice","volume":"286","author":"Perdiguero","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Luo, M., and Peng, D. (2018). ANGPTL8: An Important Regulator in Metabolic Disorders. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00169"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Guo, Z., Fan, X., Yao, J., Tomlinson, S., Yuan, G., and He, S. (2022). The role of complement in nonalcoholic fatty liver disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1017467"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e178296","DOI":"10.1172\/JCI178296","article-title":"Complement regulation in the eye: Implications for age-related macular degeneration","volume":"134","author":"Wilke","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-031-27681-1_2","article-title":"The Noncanonical Role of Complement Factor H in Retinal Pigment Epithelium (RPE) Cells and Implications for Age-Related Macular Degeneration (AMD)","volume":"1415","author":"Armento","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ong, J., Zarnegar, A., Selvam, A., Driban, M., and Chhablani, J. (2024). The Complement System as a Therapeutic Target in Retinal Disease. Medicina, 60.","DOI":"10.3390\/medicina60060945"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1111\/jgh.15631","article-title":"Circulating tumor necrosis factor-\u03b1 levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis","volume":"36","author":"Potoupni","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/09273948.2016.1277247","article-title":"Roles of IL-6 in Ocular Inflammation: A Review","volume":"26","author":"Ghasemi","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Rajeswaren, V., Wagner, B.D., Patnaik, J.L., Mandava, N., Mathias, M.T., Manoharan, N., Forest, T.E.d.C., Gnanaraj, R., Lynch, A.M., and Palestine, A.G. (2024). Elevated tumor necrosis factor alpha and vascular endothelial growth factor in intermediate age-related macular degeneration and geographic atrophy. Front. Ophthalmol., 4.","DOI":"10.3389\/fopht.2024.1356957"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Chirco, K.R., and Potempa, L.A. (2018). C-Reactive Protein As a Mediator of Complement Activation and Inflammatory Signaling in Age-Related Macular Degeneration. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00539"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/156652409787847191","article-title":"Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance and adipocytokines","volume":"9","author":"Polyzos","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000055547","article-title":"Age-related accumulation of free polyunsaturated fatty acids in human retina","volume":"31","author":"Pereira","year":"1999","journal-title":"Ophthalmic. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/17474124.2021.1949289","article-title":"Chronic liver disease and oxidative stress\u2014A narrative review","volume":"15","author":"Seen","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100858","DOI":"10.1016\/j.preteyeres.2020.100858","article-title":"Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration","volume":"79","author":"Kaarniranta","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"B\u00f6hm, E.W., Buonfiglio, F., Voigt, A.M., Bachmann, P., Safi, T., Pfeiffer, N., and Gericke, A. (2023). Oxidative stress in the eye and its role in the pathophysiology of ocular diseases. Redox Biol., 68.","DOI":"10.1016\/j.redox.2023.102967"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3892\/etm.2021.10034","article-title":"Interrelation of inflammation and oxidative stress in liver cirrhosis","volume":"21","author":"Pomacu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1617805","DOI":"10.1155\/2020\/1617805","article-title":"Role of Oxidative Stress in Hepatic and Extrahepatic Dysfunctions during Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"2020","author":"Gonzalez","year":"2020","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5935\/0004-2749.20160018","article-title":"Vitamin A and the eye: An old tale for modern times","volume":"79","author":"Faustino","year":"2016","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Sajovic, J., Megli\u010d, A., Glava\u010d, D., Markelj, M., Hawlina, M., and Fakin, A. (2022). The Role of Vitamin A in Retinal Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031014"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Zheng, Z., and Yu, X. (2024). Insulin resistance in the retina: Possible implications for certain ocular diseases. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1415521"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari, N., Androutsakos, T., Flessa, C.-M., Kyrou, I., Siasos, G., Randeva, H.S., Kassi, E., and Papavassiliou, A.G. (2022). Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells, 11.","DOI":"10.3390\/cells11162511"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Mrugacz, M., Bryl, A., and Zorena, K. (2021). Retinal Vascular Endothelial Cell Dysfunction and Neuroretinal Degeneration in Diabetic Patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030458"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.visres.2017.04.010","article-title":"The role of dyslipidemia in diabetic retinopathy","volume":"139","author":"Hammer","year":"2017","journal-title":"Vis. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/09286586.2014.949783","article-title":"Effects of fenofibric acid on diabetic macular edema: The macufen study","volume":"21","author":"Massin","year":"2014","journal-title":"Ophthalmic. Epidemiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00125-007-0897-4","article-title":"Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients","volume":"51","author":"Targher","year":"2008","journal-title":"Diabetologia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1478-3231.2008.01718.x","article-title":"Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus","volume":"29","author":"Leite","year":"2009","journal-title":"Liver Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00125-010-1720-1","article-title":"Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients","volume":"53","author":"Targher","year":"2010","journal-title":"Diabetologia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF03345421","article-title":"Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals","volume":"35","author":"Mantovani","year":"2012","journal-title":"J. Endocrinol. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2169\/internalmedicine.51.7307","article-title":"Non-alcoholic fatty liver disease is an independent predictor for macroangiopathy in Japanese type 2 diabetic patients: A cross-sectional study","volume":"51","author":"Takeuchi","year":"2012","journal-title":"Intern. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13340-011-0061-8","article-title":"Increased prevalence of diabetic complications in Japanese patients with type 1 diabetes and nonalcoholic fatty liver disease","volume":"3","author":"Yoneda","year":"2012","journal-title":"Diabetol. Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.3748\/wjg.v19.i20.3134","article-title":"Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes","volume":"19","author":"Lv","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4158\/EP14044.OR","article-title":"clinical profile of nonalcoholic fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality center in India","volume":"20","author":"Vendhan","year":"2014","journal-title":"Endocr. Prac."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jdi.12139","article-title":"Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease","volume":"5","author":"Kim","year":"2014","journal-title":"J. Diabetes Investig."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"493","DOI":"10.5455\/2320-6012.ijrms20140523","article-title":"Study of association of non alcoholic fatty liver disease (NAFLD) with micro and macrovascular complications of type 2 diabetes mellitus (T2DM)","volume":"2","author":"Somalwar","year":"2014","journal-title":"Int. J. Res. Med. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lin, T.-Y., Chen, Y.-J., Chen, W.-L., and Peng, T.-C. (2016). The Relationship between Nonalcoholic Fatty Liver Disease and Retinopathy in NHANES III. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165970"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12072-015-9607-3","article-title":"Association between retinal artery lesions and nonalcoholic fatty liver disease","volume":"9","author":"Yang","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e000904","DOI":"10.1136\/bmjdrc-2019-000904","article-title":"Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications","volume":"8","author":"Ciardullo","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/liv.14274","article-title":"Liver fibrosis by FibroScan\u00ae independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes","volume":"40","author":"Lombardi","year":"2020","journal-title":"Liver Int."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jdiacomp.2017.01.024","article-title":"Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes","volume":"31","author":"Mantovani","year":"2017","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.diabet.2018.10.001","article-title":"Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes","volume":"45","author":"Mantovani","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_124","first-page":"27","article-title":"Insulin resistance and hepatic steatosis in type 1 diabetes mellitus and their association with diabetic chronic complications","volume":"48","author":"Popa","year":"2020","journal-title":"Minerva Endocrinol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/MEG.0000000000000900","article-title":"Nonalcoholic fatty liver disease can be predicted by retinal vascular changes in patients with obesity without hypertension or diabetes","volume":"29","author":"Mummidi","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/jdi.12518","article-title":"Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications","volume":"7","author":"Yan","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_127","first-page":"330","article-title":"Liver stiffness measured by Fibroscan is associated with microvascular complications in Filipinos with Diabetes Mellitus","volume":"14","author":"Sawadjaan","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102613","DOI":"10.1016\/j.dsx.2022.102613","article-title":"Fatty liver and atherogenic dyslipidemia have opposite effects on diabetic micro- and macrovascular disease","volume":"16","author":"Hermans","year":"2022","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"108884","DOI":"10.1016\/j.diabres.2021.108884","article-title":"Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study","volume":"177","author":"Mikolasevic","year":"2021","journal-title":"Diabetes Res. Clin. Prac."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eprac.2021.02.004","article-title":"Association Between Non-Alcoholic Fatty Liver Disease and Diabetes-Related Microvascular Complications: A Retrospective Cross-Sectional Study of Hospitalized Patients","volume":"28","author":"Wen","year":"2022","journal-title":"Endocr. Prac."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/met.2024.0022","article-title":"Noninvasive Liver Fibrosis Indices as Indicators of Microvascular and Macrovascular Complications in Type 2 Diabetes","volume":"22","author":"Erman","year":"2024","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"101497","DOI":"10.1016\/j.diabet.2023.101497","article-title":"MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus","volume":"50","author":"Mantovani","year":"2024","journal-title":"Diabetes Metab."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.pcd.2019.03.009","article-title":"Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes","volume":"13","author":"Afarideh","year":"2019","journal-title":"Prim. Care Diabetes"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12944-023-01775-6","article-title":"Relationship of liver fat content with systemic metabolism and chronic complications in patients with type 2 diabetes mellitus","volume":"22","author":"Ren","year":"2023","journal-title":"Lipids Health Dis."},{"key":"ref_135","first-page":"682","article-title":"Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes","volume":"46","author":"Pons","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/0973-3930.70861","article-title":"Association of non-alcoholic fatty liver disease with diabetic microvascular and macrovascular complications in South Indian diabetic subjects","volume":"30","author":"Viswanathan","year":"2010","journal-title":"Int. J. Diabetes Dev. Ctries."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e15362","DOI":"10.1097\/MD.0000000000015362","article-title":"Presence of diabetic retinopathy is lower in type 2 diabetic patients with non-alcoholic fatty liver disease","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Deravi, N., Firouzabadi, F.D., Moosaie, F., Asadigandomani, H., Bafrani, M.A., Yoosefi, N., Poopak, A., Firouzabadi, M.D., Poudineh, M., and Rabizadeh, S. (2023). Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: A prospective cohort study. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1147458"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/joim.13673","article-title":"Increased risk for microvascular outcomes in NAFLD-A nationwide, population-based cohort study","volume":"294","author":"Ebert","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/liv.15591","article-title":"Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis","volume":"43","author":"Wang","year":"2023","journal-title":"Liver Int."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"154413","DOI":"10.1016\/j.metabol.2020.154413","article-title":"Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name","volume":"113","author":"Polyzos","year":"2020","journal-title":"Metabolism"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/1\/38\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:56:16Z","timestamp":1760115376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/1\/38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":141,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["medicina61010038"],"URL":"https:\/\/doi.org\/10.3390\/medicina61010038","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}